Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | ANPEP | P15144 | 2/20 | 0.58 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.58 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL1000408 | 1.00 | SLC7A5 (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL3280667 | 0.97 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28432049 | 0.95 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1499939 | 0.95 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL26626971 | 0.95 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL8595582 | 0.92 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL6237224 | 0.92 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL1679190 | 0.92 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL4283680 | 0.92 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL531086 | 0.92 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009343-A1 | MODULATORS OF AMYLOID AGGREGATION | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7658917-B2 | Modulators of amyloid aggregation | PRAECIS PHARMACEUTICALS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-22 | — | — | US | disclosed |
| US-20040005307-A1 | Modulators of amyloid aggregation | PRAECIS PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20020098173-A1 | Modulators of amyloid aggregation | PRAECIS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| EP-0815134-B1 | MODULATORS OF AMYLOID AGGREGATION | PRAECIS PHARM INC (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6319498-B1 | AMYLOIDOGENIC PROTEIN, OR FRAGMENT THEREOF, MODIFIED WITH CIS-DECALIN GROUP, CHOLANOYL STRUCTURE, CHOLYL GROUP, DIETHYLENETRIAMINEPENTAACETYL GROUP, MENTHOXYACETYL GROUP, FLUORESCEIN-CONTAINING GROUP, OR N-ACETYLNEURAMINYL GROUP | PRAECIS PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
| US-5854204-A | Aβ peptides that modulate β-amyloid aggregation | PRAECIS PHARMACEUTICALS, INC. (US) | 1998-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | APP, IAPP, BACE1 | SLC7A5 4371/4885ALPI 2421/4885PKM 2383/4885 |
| US-20110009343-A1 | MODULATORS OF AMYLOID AGGREGATION | APP, IAPP, APBA1 | SLC7A5 4386/4885ALPI 4002/4885PKM 2976/4885 |
| US-20040005307-A1 | Modulators of amyloid aggregation | APP, IAPP, APBA1 | SLC7A5 3877/4885ALPI 4218/4885PKM 2934/4885 |
| US-20020098173-A1 | Modulators of amyloid aggregation | APP, IAPP, APBA1 | SLC7A5 3877/4885ALPI 4218/4885PKM 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.